Details of Disease

General Information of Disease (ID: DISKW5KW)

• Disease Name: Heart disease
• Disease Class: BA41-BA42: Heart disease
• Disease Hierarchy:
  DIS01GPL: Grass pollen hypersensitivity
  DISKW5KW: Heart disease
• ICD Code:
  ICD-11: ICD-11: BA41-BA42
  ICD-9: ICD-9: 390-429
  Expand ICD-11: 'BC4Z
  Expand ICD-9: 3.90E+119
• Disease Identifiers:
  MONDO ID: MONDO_0001340
  MESH ID: D006331
  UMLS CUI: C0153500
  MedGen ID: 57787
  SNOMED CT ID: 363435002

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 3 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Adenosine triphosphate	DM79F6G	Approved	Small molecular drug	[1]
Octafluoropropane perflutren lipid microsphere	DMQM6EE	Approved	NA	[2]
Perflubutane lipid microsphere-encapsulated	DMFTQRN	Approved	NA	[3]

This Disease is Treated as An Indication in 5 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Alferminogene tadenovec	DMPH1RK	Phase 3	NA	[4]
Beperminogene perplasmid	DM6RWBN	Phase 3	NA	[5]
Prochymal	DMWTCWM	Phase 3	NA	[6]
Cenderitide	DMCT8EY	Phase 2	NA	[7]
EVP-1001-1	DMMXT7A	Phase 2	NA	[8]

This Disease is Treated as An Indication in 6 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
B-type natriuretic peptide	DMFOGH9	Discontinued in Phase 3	NA	[9]
APL-180	DMSNF1F	Discontinued in Phase 2	NA	[10]
CGS-26393	DM4U72A	Terminated	Small molecular drug	[12]
Human chorionic gonadotropin	DMA7EFM	Terminated	NA	[13]
MX-6120	DMXW67H	Terminated	NA	[14]
N-3601	DMB67FL	Terminated	NA	[15]

This Disease is Treated as An Indication in 1 Preclinical Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
PD-160170	DMB9Z4C	Preclinical	Small molecular drug	[11]

This Disease is Treated as An Indication in 6 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
FT-101	DMO3WC7	Investigative	NA	[16]
GRNCM-1	DM8W5M3	Investigative	NA	[16]
NP-02	DMQYB4L	Investigative	NA	[16]
Stem cell therapy, heart disease	DMMVSZU	Investigative	NA	[16]
StromaCel	DM19QFM	Investigative	NA	[16]
Tin-117m-labeled annexin	DM1Q2OD	Investigative	NA	[16]

Molecular Interaction Atlas (MIA) of This Disease

References

• [1] Duska Therapeutics Updates Recent Drug Development and Corporate Activities. U.S. Securities and Exchange Commission. February 16, 2005.
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [3] ClinicalTrials.gov (NCT02489045) Noninvasive Subharmonic Aided Pressure Estimation of Portal Hypertension.
• [4] Alferminogene tadenovec, an angiogenic FGF4 gene therapy for coronary artery disease. IDrugs. 2008 Apr;11(4):283-93.
• [5] ClinicalTrials.gov (NCT02144610) Safety and Efficacy of Subjects With Critical Limb Ischemia. U.S. National Institutes of Health.
• [6] ClinicalTrials.gov (NCT01233960) Evaluation of PROCHYMAL for Treatment-refractory Moderate-to-severe Crohn's Disease. U.S. National Institutes of Health.
• [7] Cenderitide (CD-NP), a novel peptide designed to activate both guanylyl cyclase B and A, activates the second messenger cGMP, suppresses aldosterone, and preserves GFR without reducing blood pressurein a proof-of-concept study in patients with chronic heart failure. BMC Pharmacol. 2011; 11(Suppl 1): P18.
• [8] ClinicalTrials.gov (NCT00881075) Safety and Efficacy of SeeMore (TM) in Heart Patients. U.S. National Institutes of Health.
• [9] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025037)
• [10] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027594)
• [11] Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
• [12] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005940)
• [13] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1160).
• [14] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018158)
• [15] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004993)
• [16] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.